



ANNUAL REPORT

2 0 2 4

MESSAGE FROM THE CHAIR DEL LEBEL

Thanks to your support, 2024 was another successful year for the Alexion Political Action Committee (AlexionPAC), enabling continued growth and reach of Alexion's advocacy efforts. This year, nearly 130 Alexion colleagues collectively contributed over \$75,000 to amplify the voice of rare disease policymaking. Our 3rd Annual Charitable PAC Match Campaign yielded \$60,100 in charitable donations to 105 unique charitable organizations, doubling our impact in our communities. AlexionPAC supported 30 bipartisan rare disease champions, with all but two winning their elections and returning to Congress. Thus, I am proud to share Alexion's fourth annual report featuring key moments from 2024, and I look forward to building on these efforts in 2025.



AlexionPAC will play a critical role as we enter the 119th Congress. The new Congress welcomes 10 new Senators and 63 new Members of the House of Representatives. As a rare disease leader, we have an imperative to educate Members of Congress about federal policies that foster innovation in rare disease, advance the best access and care, and speed diagnosis for patients. AlexionPAC will be a key tool in helping us to build relationships with these new Members, educating them on policies that will benefit rare disease patients such as the ORPHAN Cures Act, and developing the next generation of rare disease policy champions.

Looking further ahead, in alignment with Ambition 2030, we are setting annual targets in partnership with AZPAC to achieve growth with the goal of increasing our rank amongst peer pharmaceutical company PACs. We will be embarking on a comprehensive, shared strategy to boost our voice and presence as a leader in rare disease. We will focus on both increasing PAC membership and growing individual commitments. With your support, we can ensure the voice of rare disease is represented in the policymaking process.

On behalf of the AlexionPAC Board of Directors, I would like to extend my gratitude to all who supported our efforts to advocate for positive change for rare disease patients and their families. If you aren't already an AlexionPAC member, there is no time like the present to join!

Del Lebel
Del Lebel

Chair, AlexionPAC Board of Directors

Head of US Corporate Affairs




AlexionPAC 101:

A PAC, or a political action committee, is a key advocacy resource to facilitate employee engagement in the policymaking and political process. Alexion PAC furthers our goals as a company and advances the interests of our patients, employees, and other stakeholders. AlexionPAC focuses on what unites us as employees: **working to change lives for the better** –ours, people living with rare diseases, and the communities we serve. Alexion is committed to a transparent and compliant political program that advances Alexion’s strategic goals and our mission.

AlexionPAC allows you to shape the policymaking environment in support of Alexion’s mission

Gives employees direct access to the political process, and demonstrates Alexion’s commitment to policy leadership

Allows employees to pool voluntary resources to support candidates who are aligned with Alexion’s mission and values



**DIFFERENTIATE
RARE DISEASE**



**INCREASE
AWARENESS**



**ADVANCE POLICY
PRIORITIES**

ALEXIONPAC AT AKF

AKF was a great opportunity to have some fun while educating colleagues on the critical role AlexionPAC plays in developing and supporting the next generation of rare disease policy champions in the US Congress. **"Putt for the PAC" signed up 13 new PAC members at the AlexionPAC table.** THANK YOU to AlexionPAC Board Member Scott Weintraub for speaking about the importance of the PAC in our overall advocacy efforts in his opening remarks.

CHARITABLE PAC MATCH

AlexionPAC's 3rd Annual Charitable PAC Match Campaign yielded \$60,100 in charitable donations to 105 charitable organizations due to the commitment of colleagues like you, amplifying our impact in the communities where we live and work. During the campaign, Alexion matched (dollar-for-dollar) employee PAC contributions to their charity (or charities) of choice, allowing colleagues to make twice the impact with the same dollar.




\$60,100 in charitable donations



105 unique charities supported



Nearly a 10% increase from 2023



CANDIDATE CONTRIBUTIONS

AlexionPAC is non-partisan and decisions to support candidates are made independent of party affiliation.

Heading into the 2024 elections, contributions from AlexionPAC members supported 30 bipartisan rare disease policy champions with a near 50/50 split between Republican and Democrat candidate contributions. Amongst those champions, all but two candidates won their re-election. To check out the full list of candidates that received contributions, visit AlexionPAC.com.

2024 SPEAKER SERIES

Republican Strategist Rai Downs and Democratic Strategist Jonathan Jones discussed what the 2024 election results could mean for the pharmaceutical industry and policymaking in healthcare.

PAC members heard from Rep. Brett Guthrie (R-KY), chair of the House Energy and Commerce Subcommittee on Health on key health policy issues impacting the rare disease community. Very timely, as Rep. Guthrie was selected as Chair of the full Energy and Commerce Committee for the 119th Congress.

Conversation with Nathan Gonzalez, Editor & Publisher of Inside Elections Digest, who spoke about the current political environment and shared insight on the upcoming 2024 election.

More to come—join us for the 2025 AlexionPAC Speaker Series!

Alexion PAC 2024 Election Results

Thanks to the support of AlexionPAC members, Alexion is well positioned for the next Congress. AlexionPAC invested in a record number of candidates who share our company's perspective on public policies that impact our business, with a focus on innovation, science and rare disease patient-centered solutions.



Supported **30** bipartisan candidates



53% Republican



47% Democrat



93% win rate in the US House and Senate General Election

Thank You AlexionPAC Donors

DOUBLE HELIX (\$5,000)

Delman Lebel	Corporate Affairs
Denise Oleske	Research and Development
Martha Orzechowski	Medical Affairs
Tamar Thompson	Corporate Affairs
Scott Weintraub	US Commercial

HELIX (\$2,500 - \$4,999)

Jethro Ekuta	Research and Development
Jill Nichols	Medical Affairs
Matthew O'Donnell	Corporate Affairs
Todd Spalding	Legal

CATALYST (\$1,000-\$2,499)

Amy Brown	US Commercial
Michael Elloian	Finance
John Eppard	US Commercial
Jack Faragher	US Commercial
Lucille Frierson	US Commercial
Stephen Hastings	Medical Affairs
Christina Hochul	Corporate Affairs
Christophe Hotermans	Medical Affairs
John Kaye	Research and Development
Naeem Khan	Medical Affairs
David King	Legal
Mary-Sheila Leese	US Commercial
Charlene McClain	Human Experience
Cesar Melgoza	US Commercial
Kelly Morse	Research and Development
Elizabeth Preston	Corporate Affairs
Gretchen Prins	US Commercial
Brian Rosen	Corporate Affairs
Sarah Summers	Research and Development
Monique Taylor	US Commercial

INNOVATOR (\$500-\$999)

Ann Adams	Medical Affairs
Donna Ames	Research and Development
Ravinder Bajwa	Human Experience
Jennifer Bradley	Research and Development
John Bullard	US Commercial
JuliaCatini	Research and Development
Kimberly Chiarella	US Commercial
Kelly Clark	US Commercial
Lisa Feng	Corporate Affairs
ShaunFitzmorris	US Commercial
ChristyFoote	US Commercial
Lee Johnson	US Commercial
Stephen Larosa	Finance
Rochelle Liverman	Research and Development
Jennifer McKeown	US Commercial
Kelly McNeil-Posey	Medical Affairs Dept
Brian Meltzer	Research and Development
Sonali Mody	Research and Development
Dean Napoli	US Commercial
Nikoletta Pados	Research and Development
Caleb Sellers	US Commercial
John Waite	US Commercial
Yan Wang	Medical Affairs
DeborahWare	US Commercial

Thank You AlexionPAC Donors

PARTNER (\$260-\$499)

Lisa Adams	US Commercial
Sharon Bailey	US Commercial
Michelle Belliveau	Medical Affairs
Jacyntha Billingsley	US Commercial
Stephen Blumm	US Commercial
Nicole Bobo	US Commercial
Ruba Bou-Chahine	Research and Development
Kelley Brant	US Commercial
Bonnie Brogle	US Commercial
Lisa Cheney	US Commercial
Seng Cheng	Research and Development
Lance Conley	US Commercial
Corinne Copeland	US Commercial
Michelle Cosgrove	Research and Development
Grisel Crespo	US Commercial
Shari Cretella	US Commercial
Joan Curto	US Commercial
Colleen Dabbene	US Commercial
Christian Darland	US Commercial
Stacie Fauchaux	US Commercial
Samantha Gilman	Corporate Affairs Dept
Jennifer Greene	US Commercial
David Grussing	US Commercial
Karen Haire	Research and Development
Margaret Hall	US Commercial
Sarah Brett Hansen	US Commercial
David Hoover	US Commercial
Johnny Howard	US Commercial
Sonita Jimenez	US Commercial
Salma Kiani	Research and Development
Deena Kreutzer	US Commercial
Melissa Lasaro	Research and Development
Peter Lefavour	US Commercial
Christa Lizzi	US Commercial
Craig Mansfield	Human Experience
Brittany McCarron	US Commercial
Mackenzie McConville	US Commercial
Susan Mercer	Medical Affairs
Edmund Moore III	US Commercial
Elizabeth Morgan	Research and Development
Dean Oachs	US Commercial
Amisha Patel	Research and Development
Kellie Pierce	US Commercial

PARTNER CONT. (\$260-\$499)

Cynthia Rice	US Commercial
Luis Rodriguez	Corporate Affairs
Ellen Rutter	Medical Affairs
Ann Sadowsky	US Commercial
Terri Stegman	US Commercial
Elizabeth Tawil	US Commercial
Sandra Tefft	US Commercial
Jennifer Ulven	Legal
Vijay Vaidya	Technology Experience
Rebekah Whitfield	US Commercial
Matthew Wuhler	Human Experience
Bao Zhang	Research and Development
Brian Shank	Corporate Affairs
Trenna Shaw	Research and Development
Natasa Sokolovich	US Commercial

MEMBERS (LESS THAN \$260)

Terrya Addae	Research and Development
Blake Boles	Research and Development
Crystal Cope	US Commercial
Rhonda Duggan	US Commercial
Michael Enright	US Commercial
Karen Franks	US Commercial
Debra Gonzalez	US Commercial
Maria Hansen	Legal
John Moleiro	Technology Experience
Jennifer Pocoski	US Commercial
Adam Pool	US Commercial
Karen Rankin	US Commercial
Mukesh Sharma	US Commercial
Nipar Simpson	Research and Development
John Stoner	Medical Affairs
David Turpen	US Commercial
Justin Valles	Research and Development



Alexion Pharmaceuticals Inc. PAC is the federal political action committee of Alexion Pharmaceuticals Inc. Individual contributions to Alexion Pharmaceuticals Inc. PAC are used to support candidates who are running for federal office.

Contributions to Alexion Pharmaceuticals Inc. PAC are not tax deductible. Contributions are strictly voluntary and will be used for political purposes. You have the right to refuse to contribute without any reprisal. Making a contribution to Alexion Pharmaceuticals Inc. PAC does not increase your chances of winning.